Harry T. Robins

合夥人

Harry T. Robins is practice group leader for the firm’s global antitrust and competition practice. For the past 30 years, Harry has successfully represented Fortune 250 companies, leading private equity sponsors, and other prominent privately held clients. He advises on mergers and acquisitions (M&A) and joint venture transactions before the US Federal Trade Commission (FTC), the US Department of Justice (DOJ), state Attorneys General, and international regulatory agencies. He also has defended numerous clients in litigated antitrust cases and in government investigations and has been outside antitrust counsel for numerous Wall Street industry consortia.

Chambers USA commentators describe Harry as an “extraordinary antitrust merger lawyer” and a “subject matter expert who offers very practical advice,” who is “always a step ahead.” Harry frequently represents clients in transactional antitrust matters when Morgan Lewis is not retained for the corporate work on the deal across industries, with particular focus on life sciences and financial technology clients. Harry represents major clients of the firm, including Ardent Mills (flour), Axon Enterprise Inc. (military and law enforcement), Cencora, Inc. (drug wholesale, CMO), Crown Castle Inc. (telecom), Digital Bridge (private equity), The Intercontinental Exchange (fintech and exchanges), NewsCorp (publishing), Pfizer Inc. (life sciences), Sun Capital (private equity), Takeda Pharmaceutical Company (life sciences), Teleflex Corporation (medical devices), Zoetis Inc. (animal health), and Zurn Inc. (industrial manufacturing).

Due to his knowledge and experience with the Hart-Scott-Rodino Act, Harry is often quoted in the media about issues involved in this landmark antitrust legislation. His analysis of the FTC’s proposed changes to Hart-Scott-Rodino premerger rules appeared in Compliance Week and CFO.

Among his other leadership roles, Harry served as a long-time member of the firm’s Advisory Board.

On behalf of Crown Castle Inc. in its $8.5 billion sale of its enterprise fiber business to Zayo Inc. (EQT and Digital Bridge) (Department of Justice).
On behalf of Pfizer Inc. in its $10 billion acquisition of Metsera, Inc. (Federal Trade Commission)
On behalf of OTC Global Holdings in its sale to BGC Group (voice brokering) (UK CMA)
On behalf of Cencora in its $7.4 billion acquisition of OneOncology (healthcare CMO) (Department of Justice)
On behalf of Takeda Pharmaceutical Company collaboration with Ascentage Inc.
On behalf of Intercontinental Exchange, Inc. in its $16 billion proposed acquisition of Black Knight, Inc. (Federal Trade Commission)
On behalf of Amerisource Bergen in the sale of its specialty pharmacy, US Bioservices, to CVS Health. (Federal Trade Commission)
On behalf of Perrigo Co. plc in its $2.1 billion acquisition of Hera SAS (HRA Pharma) (Federal Trade Commission)
On behalf of Pfizer in connection with its spinout of Upjohn and Greenstone into a new entity called Viatris to combine with Mylan N.V. (Federal Trade Commission)
On behalf of Intercontinental Exchange Inc. in the acquisition Ellie Mae
On behalf of Aurobindo in connection with its proposed acquisition of Sandoz’s generic product portfolio (Federal Trade Commission)
On behalf of Blue Cross Blue Shield Louisiana Health Services & Indemnity Co. in connection with its proposed acquisition of Vantage Holdings, Inc. (Department of Justice)
On behalf of The Intercontinental Exchange in connection with its proposed acquisition of TMC Bonds (Department of Justice)
On behalf of Securus Technologies (Platinum Equity) in connection with its proposed acquisition of Inmate Calling Solutions (Department of Justice)
On behalf of Intercontinental Exchange in connection with its acquisition of Standard & Poor’s Securities and Evaluations business from McGraw Hill Financial (Department of Justice)
On behalf of UBM in connection with the sale of PR Newswire to GTCR (Department of Justice, UK CMA)
On behalf of Pfizer Inc. in connection with its proposed $160 billion acquisition of Allergan plc (Federal Trade Commission)
On behalf of Perrigo Company plc in connection with Mylan N.V.’s unsolicited offer to acquire Perrigo Company plc (Federal Trade Commission)
On behalf of Cargill, Inc. in connection with its joint venture with ConAgra to form flour miller Ardent Mills (Department of Justice)
On behalf of Pearson plc in connection with its joint venture of Penguin and Random House (Bertelsmann) (Department of Justice)
On behalf of Pfizer Inc. in connection with its $68 billion acquisition of Wyeth (Federal Trade Commission)
On behalf of Pearson plc in connection with its acquisition of Harcourt Assessment from Reed Elsevier (Department of Justice)

American University Washington College of Law, 1996, J.D., With Honors
Columbia University, 1990, B.A.

New York
Connecticut
US Court of Appeals for the Second Circuit
US District Court for the Southern District of New York

Publications

Events

Recipient, Matter of the Year Award, Global Competition Review (2026)

Ranked, Antitrust, New York, Chambers USA (2010–2026)

Recommended, Antitrust: Merger control, The Legal 500 US (2015–2026)

Recommended, Antitrust: Civil litigation/class actions: defense, The Legal 500 US (2025)

Listed, Lawdragon 500, Leading Global Antitrust & Competition Lawyer, Transactional Antitrust (2025, 2026)

Listed, Lawdragon 500, Leading Litigators in America, Antitrust M&A, Litigation (2022, 2024–2026)

Listed, The Best Lawyers in America, Antitrust Law, New York (2022–2026)

Notable Practitioner, IFLR1000 Financial and Corporate (2018–2023)

Member, Practice Group of the Year, Competition, Law360 (2017–2021)

Recognized, Competition, Who's Who Legal (2013–2020)

Member, Practice Group of the Year, Antitrust Law, US News & World Report and Best Lawyers (2017)

Member, American Bar Association, Antitrust Section

Executive Member, New York State Antitrust Bar Committee

Former Member, Association of the Bar of the City of New York, Antitrust and Trade Regulation Committee

News